By simultaneously targeting 2 different proteins, Bispecific antibodies are able to reap the benefits of combinatorial therapies without their disadvantages. GenScript’s Proprietary Single Domain Antibody fused to monoclonal antibody (SMAB) is leading the Bispecific revolution, with its novel structure, generation, & functionality. Check out Technology Networks interview with our leading antibody scientists to learn more about this one of a kind platform.
